Cargando…
AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells
AZD1775 is a small molecule WEE1 inhibitor used in combination with DNA-damaging agents to cause premature mitosis and cell death in p53-mutated cancer cells. Here we sought to determine the mechanism of action of AZD1775 in combination with chemotherapeutic agents in light of recent findings that A...
Autores principales: | Webster, Peter John, Littlejohns, Anna Tiffany, Gaunt, Hannah Jane, Prasad, K. Raj, Beech, David John, Burke, Dermot Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736347/ https://www.ncbi.nlm.nih.gov/pubmed/28296564 http://dx.doi.org/10.1080/15384101.2017.1301329 |
Ejemplares similares
-
AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
por: Meng, Xiangbing, et al.
Publicado: (2018) -
Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2017) -
Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer
por: Xiao, Rourou, et al.
Publicado: (2022) -
Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations
por: Serpico, Angela Flavia, et al.
Publicado: (2019) -
Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
por: Någård, Mats, et al.
Publicado: (2020)